Long-term safety with axitinib in previously treated patients with metastatic renal cell carcinoma Academic Article uri icon

Overview

MeSH Major

  • Carcinoma, Renal Cell
  • Imidazoles
  • Indazoles
  • Kidney Neoplasms
  • Protein Kinase Inhibitors

abstract

  • Declining or stable rates of most AEs support an acceptable long-term safety profile for axitinib in patients with mRCC. However, increases in the rates of some AEs warrant monitoring. This analysis is limited in that it was retrospective and included a relatively small patient population.

publication date

  • January 2015

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1016/j.clgc.2015.07.001

PubMed ID

  • 26320662

Additional Document Info

start page

  • 540

end page

  • 7.e1-7

volume

  • 13

number

  • 6